Previous studies have also demonstrated that the loss of function of FBW7 confers various chemoresistance to CRC, including regorafenib [20], trametinib [21], paclitaxel [22], 5‐fluorouracil (5‐FU) and oxaliplatin [23]. Here, FBXW7 is linked to colorectal carcinoma.